Log In
Print this Print this

Agilect, Azilect, rasagiline

Also known as: mesylate

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionIrreversible selective inhibitor of monoamine oxidase B (MAO-B)
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsSlow clinical progression of Parkinson's disease (PD); Treat early Parkinson's disease (PD); Treat early, moderate and advanced stage Parkinson's disease (PD); Treat mild cognitive impairment (MCI) in Parkinson's disease (PD); Treat moderate to advanced Parkinson's disease (PD) in patients who experience motor fluctuations; Treat Parkinson's disease (PD)
Regulatory Designation
Partner H. Lundbeck A/S; Takeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today